AKTX - CIK 0001541157
The table below shows Akari Therapeutics Plc's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.57M | -$12.55M | -$16.43M | -$7.49M | -$18.85M | -$16.95M |
| Capital expenditure | - | - | $0.00 | $142.25K | - | - |
| Investing cash flow | - | $382.00K | $0.00 | -$142.25K | - | - |
| Dividends paid | - | - | - | - | - | - |
Akari Therapeutics Plc reported operating cash flow of -$10.57M for fiscal year 2025. That is up 15.8% from -$12.55M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$24.62M (FY 2016) to -$10.57M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $13.17M | $10.99M | $7.02M | $8.14M | $14.29M | $25.07M |